South Dakota Investment Council lowered its stake in Amgen (NASDAQ:AMGN) by 59.4% during the 1st quarter, HoldingsChannel reports. The fund owned 77,041 shares of the medical research company’s stock after selling 112,589 shares during the quarter. South Dakota Investment Council’s holdings in Amgen were worth $13,134,000 at the end of the most recent quarter.
A number of other large investors also recently added to or reduced their stakes in AMGN. Geode Capital Management LLC boosted its holdings in shares of Amgen by 2.5% during the 4th quarter. Geode Capital Management LLC now owns 8,110,133 shares of the medical research company’s stock valued at $1,407,552,000 after buying an additional 199,838 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Amgen by 16.9% during the 4th quarter. Renaissance Technologies LLC now owns 4,579,445 shares of the medical research company’s stock valued at $796,365,000 after buying an additional 661,745 shares in the last quarter. LSV Asset Management boosted its holdings in shares of Amgen by 5.6% during the 1st quarter. LSV Asset Management now owns 4,028,784 shares of the medical research company’s stock valued at $686,827,000 after buying an additional 214,013 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its holdings in shares of Amgen by 3.9% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 3,304,340 shares of the medical research company’s stock valued at $574,680,000 after buying an additional 123,250 shares in the last quarter. Finally, UBS Asset Management Americas Inc. boosted its holdings in shares of Amgen by 0.5% during the 4th quarter. UBS Asset Management Americas Inc. now owns 2,827,109 shares of the medical research company’s stock valued at $491,634,000 after buying an additional 12,715 shares in the last quarter. Institutional investors and hedge funds own 78.43% of the company’s stock.
Get Amgen alerts:
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction dated Thursday, April 12th. The stock was sold at an average price of $172.68, for a total value of $263,337.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last three months, insiders sold 4,575 shares of company stock valued at $818,208. 0.19% of the stock is owned by insiders.
Shares of Amgen opened at $183.57 on Friday, Marketbeat reports. Amgen has a fifty-two week low of $157.00 and a fifty-two week high of $201.23. The company has a quick ratio of 3.60, a current ratio of 3.88 and a debt-to-equity ratio of 2.14. The stock has a market capitalization of $119.27 billion, a price-to-earnings ratio of 14.59, a price-to-earnings-growth ratio of 2.24 and a beta of 1.36.
Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, April 24th. The medical research company reported $3.47 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.24 by $0.23. Amgen had a return on equity of 35.80% and a net margin of 9.67%. The business had revenue of $5.55 billion during the quarter, compared to analyst estimates of $5.44 billion. During the same quarter in the previous year, the firm earned $3.15 EPS. Amgen’s revenue was up 1.6% on a year-over-year basis. sell-side analysts forecast that Amgen will post 13.63 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, June 8th. Shareholders of record on Thursday, May 17th will be given a $1.32 dividend. This represents a $5.28 dividend on an annualized basis and a yield of 2.88%. The ex-dividend date of this dividend is Wednesday, May 16th. Amgen’s dividend payout ratio (DPR) is 41.97%.
AMGN has been the topic of a number of research reports. Zacks Investment Research upgraded shares of Amgen from a “hold” rating to a “buy” rating and set a $194.00 target price on the stock in a report on Thursday, April 5th. Vetr raised Amgen from a “sell” rating to a “hold” rating and set a $181.60 price target for the company in a research report on Tuesday, February 27th. Morgan Stanley lowered their price target on Amgen from $204.00 to $196.00 and set an “overweight” rating for the company in a research report on Friday, February 2nd. Barclays lowered their price target on Amgen from $190.00 to $180.00 and set an “equal weight” rating for the company in a research report on Thursday, April 5th. Finally, TheStreet lowered Amgen from a “b-” rating to a “c+” rating in a research report on Wednesday, April 11th. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and ten have issued a buy rating to the company’s stock. Amgen presently has a consensus rating of “Hold” and a consensus target price of $191.70.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen (NASDAQ:AMGN).